US OptionsDetailed Quotes
RPTX250117C2500
- 0.05
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume482 Open Interest2.50Strike Price0.00Turnover406.85%IV84.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1694Delta0.3708Gamma27.60Leverage Ratio-0.0156Theta0.0000Rho4.67Eff Leverage0.0004Vega
Repare Therapeutics Stock Discussion
Sign in to post a comment
$Repare Therapeutics (RPTX.US)$
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
29 seconds ago, 4:15 AM PST
Via GlobeNewswire
RPRX
Share
• Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC
• Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
29 seconds ago, 4:15 AM PST
Via GlobeNewswire
RPRX
Share
• Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC
• Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...
1
1
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...
2
$Repare Therapeutics (RPTX.US)$ lets crack 1.80 and at least hold
1
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
1
3
NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...
*************************************
REVERSE...
63
8
my friend
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
3
10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
1
$Repare Therapeutics (RPTX.US)$ Reuters· 4 mins ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial
2
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE
No comment yet
东方韭菜 : I purchased it first, hoping the carnival won't take too long to arrive.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")